Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI)
€ 88.2 0.4 (0.46%) Market Cap: 4.51 Bil Enterprise Value: 4.55 Bil PE Ratio: 33.53 PB Ratio: 8.48 GF Score: 88/100

Q4 2023 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript

Feb 27, 2024 / 02:00PM GMT
Release Date Price: €67.5 (-5.59%)
Javier López;Belmonte;uticos ROVI
Laboratorios FarmacÃ;S.A. - Deputy Chairman & CFO

© -

Good afternoon and welcome, everybody, to this 2023 results (technical difficulty) meeting, which will start in a moment.

This is Javier López-Belmonte, ROVI's Deputy Chairman and Chief Financial Officer. Please let me introduce ROVI's attendees today. Juan López-Belmonte, Chairman and CEO; Marta Campos, Head of Finance; Beatriz de Zavala, Investor Relations; Victoria Lopez-Belmonte, Investor Relations; and myself. At the end of the presentation, a question-and-answer session will start. If you want to ask any questions during the presentation, please do not hesitate to send them through the question button on the platform.

Thank you for your presence here today. And let's now start with the presentation. I give Mr. Juan López-Belmonte the floor.

Juan López;Belmonte;uticos ROVI
Laboratorios FarmacÃ;S.A. - Chairman & CEO

© -

Thank you, Javier, and welcome to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot